Clinical Trials Logo

Clinical Trial Summary

This is an open label, phase Ia clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamic (PD) profile, immunogenicity and preliminary efficacy of JS007 in the patients with advanced solid tumors who have progressed after standard of care, or lack of effective standard therapeutic regimen. This study is divided into two periods: dose escalation period, dose expansion period.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05049265
Study type Interventional
Source Shanghai Junshi Bioscience Co., Ltd.
Contact Pan He, Postgraduate
Phone 8615172333540
Email pan_he@junshipharma.com
Status Recruiting
Phase Phase 1
Start date November 17, 2021
Completion date September 20, 2022